← Leaderboards
Dan Douer
University Of Southern California
$1,774,545
Attributed
$1,774,545
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$1,774,545 · 6
By mechanism
R41$797,566 · 2
M01$538,398 · 3
R21$438,581 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Ronald K Ross$16,986,381
- William Daniel Hillis$1,468,399
- Darryl K Shibata$11,069,880
- Smita Bhatia$27,398,641
- Susan Preston-Martin$387,362
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyHuman SubjectClinical ResearchRetinoateAcute Myelogenous LeukemiaAntineoplasticsHuman Therapy EvaluationNeoplasm /Cancer Relapse /RecurrenceDrug Screening /EvaluationNeoplasm /Cancer Nutrition TherapyNutrition Related TagVitamin TherapyMyelogenous LeukemiaLiposomesOxidesArsenicBone MarrowClinical Trial Phase INeoplasm /Cancer Palliative TreatmentClinical Trial Phase IiCombination Cancer TherapyBone Marrow PurgingBone Marrow CellsBack
Grant awards (18)
IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy$197,568
R41 · FY2007 · CA · contact PI
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$187,491
R41 · FY2006 · CA · contact PI
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$112,508
R41 · FY2006 · CA · contact PI
Arsenic Trioxide and Vitamin C in AML$219,375
R21 · FY2005 · CA
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$299,999
R41 · FY2004 · CA
Arsenic Trioxide and Vitamin C in AML$219,206
R21 · FY2004 · CA
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2002 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$0
M01 · FY2002 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$155,764
M01 · FY2001 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$155,764
M01 · FY2001 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2001 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$0
M01 · FY2001 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$155,764
M01 · FY2000 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$35,553
M01 · FY2000 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$35,553
M01 · FY2000 · RR
COMPASSIONATE USE OF ARSENIC TRIOXIDE IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2000 · RR
COMPASSIONATE USE OF ARSENIC TRIOXIDE IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2000 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2000 · RR